|
Sep 1
|
Goldman Sachs Growth Stocks: Top 12 Stocks
|
|
Aug 31
|
Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list
|
|
Aug 30
|
Medicare's drug pricing list didn't impact company stocks — here's why
|
|
Aug 30
|
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
|
|
Aug 30
|
Medicare price negotiation list: What it means for pharma companies
|
|
Aug 29
|
Expensive Drugs Targeted for First U.S. Price Negotiations
|
|
Aug 29
|
Eli Lilly and Other Pharma Stocks Are Ignoring Medicare’s 10 Drug List
|
|
Aug 29
|
Steady Eddies: 7 Unshakeable Stocks for Any Type of Market
|
|
Aug 29
|
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
|
|
Aug 29
|
Best Buy results, Medicare negotiations list, Hurricane Idalia: Top stories
|
|
Aug 29
|
Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations
|
|
Aug 29
|
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
|
|
Aug 29
|
Merck to Participate in the Citi 18th Annual BioPharma Conference
|
|
Aug 28
|
Unveiling Merck (MRK)'s Value: Is It Really Priced Right? A Comprehensive Guide
|
|
Aug 28
|
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
|
|
Aug 28
|
Oncology Market's Huge Potential Puts These Stocks in Focus
|
|
Aug 28
|
Has Merck & Co., Inc. (NYSE:MRK) Stock's Recent Performance Got Anything to Do With Its Financial Health?
|
|
Aug 27
|
13 Best Defensive Stocks To Buy Now
|
|
Aug 25
|
AstraZeneca files lawsuit against U.S. over drug pricing
|
|
Aug 25
|
UPDATE 2-Merck, Eisai discontinue late-stage study for combo cancer therapy
|